Laurus Labs’ Q2 FY26 revenue grew 35.1% YoY to Rs 16.5 billion.

(Photo source: company website) The non-ARV formulation sales have witnessed a healthy scale-up QoQ, fueled by newer introductions and higher off-take of existing products. Laurus Labs has shown encouraging performance in the ARV segment, led by higher volumes of products sold during the quarter.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page